451 related articles for article (PubMed ID: 18041064)
1. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.
Zhu AX
Cancer; 2008 Jan; 112(2):250-9. PubMed ID: 18041064
[TBL] [Abstract][Full Text] [Related]
2. Molecular therapy for the treatment of hepatocellular carcinoma.
Greten TF; Korangy F; Manns MP; Malek NP
Br J Cancer; 2009 Jan; 100(1):19-23. PubMed ID: 19018262
[TBL] [Abstract][Full Text] [Related]
3. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
Kim R; Byrne MT; Tan A; Aucejo F
Oncology (Williston Park); 2011 Mar; 25(3):283-91, 295. PubMed ID: 21548473
[TBL] [Abstract][Full Text] [Related]
4. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?
Zhu AX
Oncologist; 2006; 11(7):790-800. PubMed ID: 16880238
[TBL] [Abstract][Full Text] [Related]
5. Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.
Rini BI; Sosman JA; Motzer RJ
BJU Int; 2005 Aug; 96(3):286-90. PubMed ID: 16042715
[No Abstract] [Full Text] [Related]
6. [Targeted therapies in hepatocellular carcinoma].
Bouattour M; Marijon H; Dreyer C; Faivre S; Raymond E
Presse Med; 2010; 39(7-8):753-64. PubMed ID: 20378303
[TBL] [Abstract][Full Text] [Related]
7. [New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
Hagymási K; Tulassay Z
Orv Hetil; 2010 Oct; 151(43):1763-8. PubMed ID: 20940115
[TBL] [Abstract][Full Text] [Related]
8. Systemic treatment of hepatocellular carcinoma: dawn of a new era?
Zhu AX
Ann Surg Oncol; 2010 May; 17(5):1247-56. PubMed ID: 20405329
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
[TBL] [Abstract][Full Text] [Related]
10. Selection of patients with hepatocellular carcinoma for sorafenib.
Abou-Alfa GK
J Natl Compr Canc Netw; 2009 Apr; 7(4):397-403. PubMed ID: 19406040
[TBL] [Abstract][Full Text] [Related]
11. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Cabebe E; Wakelee H
Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
[TBL] [Abstract][Full Text] [Related]
12. Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib.
Wich C; Agaimy A; Strobel D; Wissniowski TT; Hartmann A; Ocker M
World J Gastroenterol; 2010 Jul; 16(28):3592-6. PubMed ID: 20653070
[TBL] [Abstract][Full Text] [Related]
13. Trials probe new agents for kidney cancer.
Hampton T
JAMA; 2006 Jul; 296(2):155-7. PubMed ID: 16835411
[No Abstract] [Full Text] [Related]
14. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.
Wörns MA; Schuchmann M; Düber C; Otto G; Galle PR; Weinmann A
Oncology; 2010; 79(1-2):85-92. PubMed ID: 21071995
[TBL] [Abstract][Full Text] [Related]
15. Developing better treatments in hepatocellular carcinoma.
Duffy A; Greten T
Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):551-60. PubMed ID: 20932140
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy in renal cell carcinoma.
Vakkalanka BK; Rini BI
Curr Opin Urol; 2008 Sep; 18(5):481-7. PubMed ID: 18670271
[TBL] [Abstract][Full Text] [Related]
18. Targeted agents and systemic therapy in hepatocellular carcinoma.
Ang C; O'Reilly EM; Abou-Alfa GK
Recent Results Cancer Res; 2013; 190():225-46. PubMed ID: 22941024
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
20. Molecularly targeted therapy in renal cell carcinoma: where do we go from here?
Rini BI
Expert Rev Anticancer Ther; 2006 Dec; 6(12):1753-60. PubMed ID: 17181489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]